{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:16:55Z","timestamp":1779189415573,"version":"3.51.4"},"reference-count":142,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35HL150682, RO1AI138348, PO1AI089473"],"award-info":[{"award-number":["R35HL150682, RO1AI138348, PO1AI089473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Severe respiratory viral infections, such as influenza, metapneumovirus (HMPV), respiratory syncytial virus (RSV), rhinovirus (RV), and coronaviruses, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), cause significant mortality and morbidity worldwide. These viruses have been identified as important causative agents of acute respiratory disease in infants, the elderly, and immunocompromised individuals. Clinical signs of infection range from mild upper respiratory illness to more serious lower respiratory illness, including bronchiolitis and pneumonia. Additionally, these illnesses can have long-lasting impact on patient health well beyond resolution of the viral infection. Aside from influenza, there are currently no licensed vaccines against these viruses. However, several research groups have tested various vaccine candidates, including those that utilize attenuated virus, virus-like particles (VLPs), protein subunits, and nanoparticles, as well as recent RNA vaccines, with several of these approaches showing promise. Historically, vaccine candidates have advanced, dependent upon the ability to activate the humoral immune response, specifically leading to strong B cell responses and neutralizing antibody production. More recently, it has been recognized that the cellular immune response is also critical in proper resolution of viral infection and protection against detrimental immunopathology associated with severe disease and therefore, must also be considered when analyzing the efficacy and safety of vaccine candidates. These candidates would ideally result in robust CD4+ and CD8+ T cell responses as well as high-affinity neutralizing antibody. This review will aim to summarize established and new approaches that are being examined to harness the cellular immune response during respiratory viral vaccination.<\/jats:p>","DOI":"10.3390\/vaccines8040783","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T09:41:41Z","timestamp":1608543701000},"page":"783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Harnessing Cellular Immunity for Vaccination against Respiratory Viruses"],"prefix":"10.3390","volume":"8","author":[{"given":"Nicholas W.","family":"Lukacs","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA"},{"name":"Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-5921","authenticated-orcid":false,"given":"Carrie-Anne","family":"Malinczak","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global Burden of Disease Study 2015","volume":"17","author":"Troeger","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0140-6736(12)61901-1","article-title":"Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: A systematic analysis","volume":"381","author":"Nair","year":"2013","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.4049\/jimmunol.1401410","article-title":"Vaccines against Respiratory Viral Pathogens for Use in Neonates: Opportunities and Challenges","volume":"193","year":"2014","journal-title":"J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","article-title":"Respiratory Syncytial Virus\u2014A Comprehensive Review","volume":"45","author":"Borchers","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coviro.2016.01.003","article-title":"Determinants of early life immune responses to RSV infection","volume":"16","author":"Ruckwardt","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_6","first-page":"373","article-title":"Risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants","volume":"52","author":"Zhang","year":"2014","journal-title":"Zhonghua Chin. J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12948-020-00129-2","article-title":"A gendered magnifying glass on COVID-19","volume":"18","author":"Salvati","year":"2020","journal-title":"Clin. Mol. Allergy"},{"key":"ref_8","first-page":"1775","article-title":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lipsky, M.S., and Hung, M. (2020). Men and COVID-19: A Pathophysiologic Review. Am. J. Men\u2019s Health, 14.","DOI":"10.1177\/1557988320954021"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/thx.2009.121582","article-title":"Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life","volume":"65","author":"Sigurs","year":"2010","journal-title":"Thorax"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","article-title":"Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis","volume":"375","author":"Nair","year":"2010","journal-title":"Lancet Lond. Engl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaci.2016.01.002","article-title":"The contributions of allergic sensitization and respiratory pathogens to asthma inception","volume":"137","author":"Jackson","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(10)61380-3","article-title":"Role of viral respiratory infections in asthma and asthma exacerbations","volume":"376","author":"Busse","year":"2010","journal-title":"Lancet Lond. Engl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41586-020-02598-6","article-title":"The lasting misery of coronavirus long-haulers","volume":"585","author":"Marshall","year":"2020","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"(2020). Understanding the long-term health effects of COVID-19. EClinicalMedicine, 26, 100586.","DOI":"10.1016\/j.eclinm.2020.100586"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/oxfordjournals.aje.a120956","article-title":"Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine","volume":"89","author":"Fulginiti","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/oxfordjournals.aje.a120954","article-title":"An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine","volume":"89","author":"Kapikian","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-Induced Enhanced Disease Illness","volume":"9","author":"Smatti","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease","volume":"23","author":"Acosta","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nm0109-21","article-title":"Fixing a failed vaccine","volume":"15","author":"Varga","year":"2009","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/all.14310","article-title":"Inhibition of uric acid or IL-1\u03b2 ameliorates respiratory syncytial virus immunopathology and development of asthma","volume":"75","author":"Schuler","year":"2020","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41385-019-0171-3","article-title":"Sex-associated TSLP-induced immune alterations following early-life RSV infection leads to enhanced allergic disease","volume":"12","author":"Malinczak","year":"2019","journal-title":"Mucosal Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/CMR.18.3.541-555.2005","article-title":"Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection","volume":"18","author":"Openshaw","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0167-5699(96)80606-2","article-title":"The expanding universe of T-cell subsets: Th1, Th2 and more","volume":"17","author":"Mosmann","year":"1996","journal-title":"Immunol. Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of Effector CD4 T Cell Populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4+ T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.4110\/in.2018.18.e33","article-title":"Direct Antiviral Mechanisms of Interferon-Gamma","volume":"18","author":"Kang","year":"2018","journal-title":"Immune Netw."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","article-title":"Th1\/Th2 cells","volume":"5","author":"Romagnani","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/COH.0b013e328335c2f6","article-title":"Th17 cytokines in mucosal immunity and inflammation","volume":"5","author":"Guglani","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2014.00466","article-title":"Immunity to RSV in Early-Life","volume":"5","author":"Lambert","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajpath.2011.03.003","article-title":"IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease","volume":"179","author":"Mukherjee","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11882-012-0278-z","article-title":"Mechanisms of Respiratory Syncytial Virus Modulation of Airway Immune Responses","volume":"12","author":"Lotz","year":"2012","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.immuni.2008.04.018","article-title":"Selective CD4 T cell help for antibody responses to a large viral pathogen: Deterministic linkage of specificities","volume":"28","author":"Sette","year":"2008","journal-title":"Immunity"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41591-020-0858-8","article-title":"T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers","volume":"26","author":"Arunachalam","year":"2020","journal-title":"Nat. Med."},{"key":"ref_38","first-page":"1","article-title":"Understanding the T cell immune response in SARS coronavirus infection","volume":"1","author":"Oh","year":"2012","journal-title":"Emerg. Microbes Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/317537","article-title":"Type 1\/Type 2 Immunity in Infectious Diseases","volume":"32","author":"Spellberg","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P.C., Garron, T., Atmar, R.L., Peters, C.J., and Couch, R.B. (2012). Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE, 7.","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2217\/fvl.11.62","article-title":"Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection","volume":"6","author":"McDermott","year":"2011","journal-title":"Future Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1084\/jem.20052359","article-title":"Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus","volume":"203","author":"Smit","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1189\/jlb.0412195","article-title":"Respiratory syncytial virus infection modifies and accelerates pulmonary disease via DC activation and migration","volume":"94","author":"Jang","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.immuni.2006.08.007","article-title":"Type I interferons in host defense","volume":"25","author":"Stetson","year":"2006","journal-title":"Immunity"},{"key":"ref_46","first-page":"3","article-title":"Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1128\/JVI.79.14.9315-9319.2005","article-title":"Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Mediate Inhibition of Stat2 Expression and Alpha\/Beta Interferon Responsiveness","volume":"79","author":"Lo","year":"2005","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12191","DOI":"10.1128\/JVI.01604-08","article-title":"The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes","volume":"82","author":"Bukreyev","year":"2008","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gabriele, L., Fragale, A., Romagnoli, G., Parlato, S., Lapenta, C., Santini, S.M., Ozato, K., and Capone, I. (2020). Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19. Cytokine Growth Factor Rev., epublication, ahead of press.","DOI":"10.1016\/j.cytogfr.2020.10.001"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: A program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2017.12.034","article-title":"Immune Training Unlocks Innate Potential","volume":"172","author":"Song","year":"2018","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-030-28524-1_2","article-title":"Trained Innate Immunity and Its Implications for Mucosal Immunity and Inflammation","volume":"1197","author":"Hajishengallis","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","article-title":"Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes","volume":"109","author":"Kleinnijenhuis","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3389\/fimmu.2019.02806","article-title":"BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design","volume":"10","author":"Vasquez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.vaccine.2004.09.006","article-title":"Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls community based case-control study","volume":"23","author":"Stensballe","year":"2005","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1016\/j.vaccine.2020.08.018","article-title":"The effect of Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic","volume":"38","author":"Yitbarek","year":"2020","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mohapatra, P.R., Mishra, B., and Behera, B. (2020). BCG vaccination induced protection from COVID-19. Indian J. Tuberc., epublication, ahead of press.","DOI":"10.1016\/j.ijtb.2020.08.004"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Rivas, M.N., Ebinger, J.E., Wu, M., Sun, N., Braun, J., Sobhani, K., Eyk, J.E.V., Cheng, S., and Arditi, M. (2020). BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. J. Clin. Investig.","DOI":"10.1172\/JCI145157"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Fidel, P.L., and Noverr, M.C. (2020). Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?. mBio, 11.","DOI":"10.1128\/mBio.00907-20"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ashford, J.W., Gold, J.E., Huenergardt, M.A., Katz, R.B.A., Strand, S.E., Bolanos, J., Wheeler, C.J., Perry, G., Smith, C.J., and Steinman, L. (2020). MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness. Am. J. Med., epublication, ahead of press.","DOI":"10.1016\/j.amjmed.2020.10.003"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Larenas-Linnemann, D.E., and Rodr\u00edguez-Monroy, F. (2020). Thirty-six COVID-19 cases preventively vaccinated with mumps-measles-rubella vaccine: All mild course. Allergy, epublication, ahead of press.","DOI":"10.22541\/au.159682241.15603325"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2000076","DOI":"10.1002\/bies.202000076","article-title":"Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?","volume":"42","year":"2020","journal-title":"BioEssays"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.4049\/jimmunol.0802262","article-title":"Subversion of Pulmonary Dendritic Cell Function by Paramyxovirus Infections","volume":"182","author":"Kolli","year":"2009","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.20070891","article-title":"Sustained desensitization to bacterial Toll-like receptor ligands after resolutionof respiratory influenza infection","volume":"205","author":"Didierlaurent","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Low, J.S., Farsakoglu, Y., Amezcua Vesely, M.C., Sefik, E., Kelly, J.B., Harman, C.C.D., Jackson, R., Shyer, J.A., Jiang, X., and Cauley, L.S. (2020). Tissue-resident memory T cell reactivation by diverse antigen-presenting cells imparts distinct functional responses. J. Exp. Med., 217.","DOI":"10.1084\/jem.20192291"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","article-title":"T-cell-inducing vaccines\u2014What\u2019s the future","volume":"135","author":"Gilbert","year":"2012","journal-title":"Immunology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/infdis\/jiq162","article-title":"Smallpox vaccine safety is dependent on T cells and not B cells","volume":"203","author":"Gordon","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e00141-18","DOI":"10.1128\/JVI.00141-18","article-title":"Intrastructural Help: Harnessing T-Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines","volume":"92","author":"Elsayed","year":"2018","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ni.2844","article-title":"Vaccines that stimulate T cell immunity to HIV-1: The next step","volume":"15","author":"McMichael","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/21645515.2017.1381809","article-title":"Characterization of T-cell immune responses in clinical trials of the candidate RTS, S malaria vaccine","volume":"14","author":"Moris","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.vaccine.2018.03.023","article-title":"T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development","volume":"36","author":"Nlinwe","year":"2018","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.xcrm.2020.100095","article-title":"Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants","volume":"1","author":"Marinaik","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/eji.200737254","article-title":"Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes","volume":"37","author":"Stoloff","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.vaccine.2014.06.006","article-title":"A novel peptide-based pan-influenza A vaccine: A double blind, randomised clinical trial of immunogenicity and safety","volume":"33","author":"Francis","year":"2015","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","article-title":"Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.1016\/j.vaccine.2020.08.023","article-title":"Formulation of the prefusion RSV F protein with a Th1\/Th2-balanced adjuvant provides complete protection without Th2-skewed immunity in RSV-experienced young mice","volume":"38","author":"Kosanovich","year":"2020","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4049\/jimmunol.1900741","article-title":"Upregulation of H3K27 Demethylase KDM6 During Respiratory Syncytial Virus Infection Enhances Proinflammatory Responses and Immunopathology","volume":"204","author":"Malinczak","year":"2019","journal-title":"J. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ptaschinski, C., Mukherjee, S., Moore, M.L., Albert, M., Helin, K., Kunkel, S.L., and Lukacs, N.W. (2015). RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In Vivo. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004978"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"106717","DOI":"10.1016\/j.intimp.2020.106717","article-title":"Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses","volume":"86","author":"Gupta","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.vaccine.2013.02.043","article-title":"Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats","volume":"31","author":"Kamphuis","year":"2013","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Shafique, M., Meijerhof, T., Wilschut, J., and de Haan, A. (2013). Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: Effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061287"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.vaccine.2009.03.026","article-title":"TLR9 Agonist, but Not TLR7\/8, Functions As An Adjuvant To Diminish FI-RSV Vaccine-Enhanced Disease, While Either Agonist Used as Therapy During Primary RSV Infection Increases Disease Severity","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent Advances in the Discovery and Delivery of TLR7\/8 Agonists as Vaccine Adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"ImmunoHorizons"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB\/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine","volume":"88","author":"Uda","year":"2014","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1128\/JVI.01410-12","article-title":"Intranasal Treatment with Poly(I\u00b7C) Protects Aged Mice from Lethal Respiratory Virus Infections","volume":"86","author":"Zhao","year":"2012","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/vim.2007.0079","article-title":"Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine","volume":"21","author":"Gai","year":"2008","journal-title":"Viral Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1016\/j.vaccine.2011.06.100","article-title":"The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848","volume":"29","author":"Zhao","year":"2011","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e01339-14","DOI":"10.1128\/mBio.01339-14","article-title":"Acellular Pertussis Vaccines and Pertussis Resurgence: Revise or Replace?","volume":"5","author":"Ausiello","year":"2014","journal-title":"mBio"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-Based Vaccines Against Respiratory Viruses","volume":"10","author":"Gauthier","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1039\/C5BM00360A","article-title":"Nanostructures for protein drug delivery","volume":"4","author":"Lopes","year":"2016","journal-title":"Biomater. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Lindell, D.M., Morris, S.B., White, M.P., Kallal, L.E., Lundy, P.K., Hamouda, T., Baker, J.R., and Lukacs, N.W. (2011). A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021823"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.1301424","article-title":"Distinct Pathways of Humoral and Cellular Immunity Induced with the Mucosal Administration of a Nanoemulsion Adjuvant","volume":"192","author":"Bielinska","year":"2014","journal-title":"J. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1080\/21645515.2015.1075680","article-title":"Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats","volume":"11","author":"Makidon","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Anderson, E.J., Rouphael, N.G., Widge, A.T., Jackson, L.A., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., and Pruijssers, A.J. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med., epublication, ahead of press.","DOI":"10.1056\/NEJMoa2028436"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Callaway, E. (2020). What Pfizer\u2019s landmark COVID vaccine results mean for the pandemic. Nature, Available online: https:\/\/www.nature.com\/articles\/d41586-020-03166-8.","DOI":"10.1038\/d41586-020-03166-8"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kim, A.-R., Lee, D.-H., Lee, S.-H., Rubino, I., Choi, H.-J., and Quan, F.-S. (2018). Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191277"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/infdis\/jir474","article-title":"Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice","volume":"204","author":"Quan","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"11692","DOI":"10.1128\/JVI.02018-15","article-title":"Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells","volume":"89","author":"Kim","year":"2015","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2567.2010.03231.x","article-title":"Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice","volume":"130","author":"Lu","year":"2010","journal-title":"Immunology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","article-title":"Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice","volume":"140","author":"Wang","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet Lond. Engl."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Gars, M.L., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A.M., Stoop, J., Tete, S., Damme, W.V., and Leroux-Roels, I. (2020). Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: Interim results of a phase 1\/2a, double-blind, randomized, placebo-controlled trial. medRxiv, preprint.","DOI":"10.1101\/2020.09.23.20199604"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.vaccine.2015.08.056","article-title":"Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats","volume":"33","author":"Widjojoatmodjo","year":"2015","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/mt.2013.142","article-title":"Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation","volume":"22","author":"Johnson","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/mtm.2015.18","article-title":"Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates","volume":"2","author":"Pierantoni","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"300ra127","DOI":"10.1126\/scitranslmed.aac5757","article-title":"Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections","volume":"7","author":"Taylor","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","article-title":"First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector\u2013Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sayedahmed, E.E., Elkashif, A., Alhashimi, M., Sambhara, S., and Mittal, S.K. (2020). Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8040574"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/JVI.80.4.1959-1964.2006","article-title":"Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization","volume":"80","author":"Gao","year":"2006","journal-title":"J. Virol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","article-title":"Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice","volume":"367","author":"Hoelscher","year":"2006","journal-title":"Lancet Lond. Engl."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1203\/PDR.0b013e31819f195d","article-title":"Developmental Biology of the Innate Immune Response: Implications for Neonatal and Infant Vaccine Development","volume":"65","author":"Philbin","year":"2009","journal-title":"Pediatr. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.immuni.2017.03.009","article-title":"Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny","volume":"46","author":"Kollmann","year":"2017","journal-title":"Immunity"},{"key":"ref_136","first-page":"83","article-title":"Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines","volume":"60","author":"Sweet","year":"1987","journal-title":"Immunology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41467-018-04216-6","article-title":"Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model","volume":"9","author":"Blanco","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1016\/j.vaccine.2017.06.009","article-title":"Preclinical assessment of safety of maternal vaccination against respiratory syncytial virus (RSV) in cotton rats","volume":"35","author":"Blanco","year":"2017","journal-title":"Vaccine"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1016\/j.ajog.2011.02.042","article-title":"Impact of maternal immunization on influenza hospitalizations in infants","volume":"204","author":"Poehling","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e1453","DOI":"10.1542\/peds.2010-0507","article-title":"Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis","volume":"126","author":"Bhore","year":"2010","journal-title":"Pediatrics"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1874285801105010144","article-title":"Risk Factors for Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection","volume":"5","author":"Sommer","year":"2011","journal-title":"Open Microbiol. J."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:47:51Z","timestamp":1760179671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":142,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040783"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040783","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]}}}